Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2011-02-08
2011-02-08
Skelding, Zachary (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S154100, C514S825000, C514S863000, C514S866000, C514S885000, C514S903000
Reexamination Certificate
active
07883703
ABSTRACT:
The invention provides novel methods of administering anti-CD3 antibodies, e.g., via oral or mucosal delivery. The invention also provides methods of treating, preventing, or delaying the onset of autoimmune disorders by oral or mucosal administration of anti-CD3 antibodies. Finally, the invention provides compositions including anti-CD3 antibodies, suitable for oral or mucosal administration.
REFERENCES:
patent: 4361549 (1982-11-01), Kung et al.
patent: 4515893 (1985-05-01), Kung et al.
patent: 4654210 (1987-03-01), Kung et al.
patent: 5556763 (1996-09-01), Ochoa et al.
patent: 5658570 (1997-08-01), Newman et al.
patent: 5681722 (1997-10-01), Newman et al.
patent: 5693780 (1997-12-01), Newman et al.
patent: 5711937 (1998-01-01), Nishida et al.
patent: 5750105 (1998-05-01), Newman et al.
patent: 5756096 (1998-05-01), Newman et al.
patent: 5834597 (1998-11-01), Tso et al.
patent: 6030613 (2000-02-01), Blumberg et al.
patent: 6090380 (2000-07-01), Weisbart
patent: 6143297 (2000-11-01), Bluestone
patent: 6197328 (2001-03-01), Yanagawa
patent: 6406696 (2002-06-01), Bluestone
patent: 6576651 (2003-06-01), Bandyopadhyay et al.
patent: 7041289 (2006-05-01), Bach et al.
patent: 2002/0150580 (2002-10-01), Newman et al.
patent: 2003/0235536 (2003-12-01), Blumberg et al.
patent: 2005/0042664 (2005-02-01), Wu et al.
patent: 2007/0117778 (2007-05-01), Ilan
patent: 2002-506420 (2002-02-01), None
patent: 2002-542205 (2002-12-01), None
patent: WO 90/08540 (1990-08-01), None
patent: WO 93/02108 (1993-02-01), None
patent: WO 9814209 (1998-04-01), None
patent: WO 9847531 (1998-10-01), None
patent: WO 01/37860 (2001-05-01), None
patent: WO 0130300 (2001-05-01), None
patent: WO 0154721 (2001-08-01), None
patent: WO 01/94419 (2001-12-01), None
patent: WO03009812 (2003-02-01), None
patent: WO 03026692 (2003-04-01), None
patent: WO03067221 (2003-08-01), None
patent: WO03068934 (2003-08-01), None
patent: WO2005048935 (2005-06-01), None
patent: WO2009090656 (2009-07-01), None
Utset, J Rheumatol. Sep. 2002;29(9):1907-13.
De Kozak et al., Int Rev Immunol. Mar.-Jun. 2002;21(2-3):231-53.
Groux et al., Nature. Oct. 16, 1997;389(6652):737-42.
Del Zotto et al., Clin Exp Immunol. Oct. 2003;134(1):120-6.
Selman et al., Ann Intern Med. Jan. 16, 2001;134(2):136-51.
Chen et al., J Immunol. Dec. 1, 2002;169(11):6530-8.
Czernok et al., Clin Exp Immunol. Jul. 1996;105(1):104-11.
Johansson et al., Curr Opin Infect Dis. Feb 2003;16(1):43-9.
Heldin et al., Cell. Jan 27, 1995;80(2):213-23.
Kozlowski et al., Acta Neuropathol. 1987;74(2):163-8.
Utset et al., J Rheumatol 2002;29:1907-13.
Appelbaum, “Haematopoietic cell transplantation as immunotherapy,”Nature, 411:385-389 (2001).
Barnes et al., “A randomised trial of oral gammaglobulin in low-birth-weight infants infected with rotavirus,”Lancet, 1(8286):1371-1373 (1982).
Belghith et al., “TGF-β-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes,”Nat. Med., 9(9):1202-1208 (2003).
Chatenoud, “CD3-specific antibody-induced active tolerance: from bench to bedside,”Nat. Rev. Immunol., 3:123-132 (2003).
Chatenoud et al., “CD3 Antibody-Induced Dominant Self Tolerance in Overtly Diabetic NOD Mice,”J. Immunol., 158:2947-2954 (1997).
Cleland et al., “Mucosal tolerance and rheumatoid arthritis,”Br. J. Rheumatol., 36(11):1139-1141 (1997).
Cosimi et al., “Treatment of acute renal allograft rejection with OKT3 monoclonal antibody,”Transplantation, 32(6):535-539 (1981).
Cosimi et al., “Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts,”N. Engl. J. Med., 305(6):308-314 (1981).
Herold et al., “Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus,”N. Engl. J. Med., 346(22):1692-1698 (2002).
Hill et al., “T-Helper 1—Type Immunity to Trophoblast in Women With Recurrent Spontaneous Abortion,”JAMA, 273(24):1933-1936 (1995).
Iijima et al., “Mucosal immune network in the gut for the control of infectious diseases,”Rev. Med. Virol., 11:117-133 (2001).
Jameson, “Maintaining the Norm: T-Cell Homeostasis,”Nat. Rev. Immunol., 2(8):547-556 (2002).
Londei et al., “Efficient Propagation and Cloning of Human T Cells in the Absence of Antigen by Means of OKT3, Interleukin 2, and Antigen-Presenting Cells,”Scand. J. Immunol., 27:35-46 (1988).
Lu et al., “A Novel Population of Expanded Human CD3+CD56+Cells Derived from T Cells with Potent In Vivo Antitumor Activity in Mice with Severe Combined Immunodeficiency,”J. Immunol., 153(4):1687-1696(1994).
MacLean et al., “T Cell-dependent Regulation of Eotaxin in Antigen-induced Pulmonary Eosinophila,”J. Exp. Med., 184(4):1461-1469 (1996).
“Orthoclone OKT3 Prescribing Information—Clinical Pharmacology,” Ortho Biotech Products, L.P., http://healthcareprofessionals.orthobiotech.com/products/orthoclone/pi—pharmacology.jsp, 2 pages (Jun. 2, 2003).
“Orthoclone OKT3 Prescribing Information—Description,” Ortho Biotech Products, L.P., http://healthcareprofessionals.orthobiotech.com/products/orthoclone/pi—description.jsp, 1 page (Jun. 2, 2003).
“Orthoclone OKT3 Prescribing Information—Dosage and Administration,” Ortho Biotech Products, L.P., http://healthcareprofessionals.orthobiotech.com/products/orthoclone/pi—dosage.jsp, 2 pages (Jun. 2, 2003).
Pacyna et al., “Survival of Rotavirus Antibody Activity Derived From Bovine Colostrum After Passage Through the Human Gastrointestinal Tract,”J. Pediatr. Gastroenterol. Nutr., 32(2):162-167 (2001).
Petrovsky et al., “Prospects for the Prevention and Reversal of Type 1 Diabetes Mellitus,”Drugs, 62(18):2617-2635 (2002).
Reilly et al., “Oral Delivery of Antibodies: Future Pharmacokinetic Trends,”Clin. Pharmacokinet., 32(4):313-323 (1997).
Salles et al., “Changes in the leucocyte subpopulations of the palatine tonsillar crypt epithelium of pigs in response toStreptococcus suistype 2 infection,”Vet. Immunol. Immunopathol., 87:51-63 (2002).
Seung et al., “Allogeneic hematopoietic chimerism in mice treated with sublethal myeloablation and anti-CD154 antibody: absence of graft-versus-host disease, induction of skin allograft tolerance, and prevention of recurrent autoimmunity in islet-allografted NOD/Lt mice,”Blood, 95(6):2175-2182 (2000).
Tran et al., “Reversal of experimental allergic encephalomyelitis with non-mitogenic, non-depleting anti-CD3 mAb therapy with a preferential effect on Th1 cells that is augmented by IL-4,”Int. Immunol., 13(9):1109-1120 (2001).
Viglietta et al., “Loss of Functional Suppression by CD4+CD25+Regulatory T Cells in Patients with Multiple Sclerosis,”J. Exp. Med., 199(7):971-979 (2004).
Weiner, “Current Issues in the Treatment of Human Diseases by Mucosal Tolerance,”Ann. N.Y. Acad. Sci., 1029:211-224 (2004).
Weiner, “Immunosuppressive treatment in multiple sclerosis,”J. Neurol. Sci., 223:1-11 (2004).
Weiner, “Multiple Sclerosis Is an Inflammatory T-Cell—Mediated Autoimmune Disease,”Arch. Neurol., 61:1613-1615 (2004).
Weiner, “Oral tolerance, an active immunologic process mediated by multiple mechanisms,”J. Clin. Invest., 106(8):935-937 (2000).
Weinshenker et al., “An open trial of OKT3 in patients with multiple sclerosis,”Neurology, 41(7):1047-1052 (1991).
Wilson et al., “Multiple differences in gene expression in regulatory Vα24JαQ T cells from identical twins discordant for type I diabetes,”Proc. Natl. Acad. Sci. USA, 97(13):7411-7416 (2000).
Faria et al., “Oral tolerance: mechanisms and therapeutic applications,”Adv. Immunol., 73:153-164 (1999).
Goldstein et al., “A randomized clinical trial of OKT-3 monoclonal antibody for acute rejection of
Sayegh Mohamed H.
Weiner Howard L.
Fish & Richardson P.C.
Skelding Zachary
The Brigham and Women's Hospital, Inc.
LandOfFree
Methods of modulating immunity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of modulating immunity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of modulating immunity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2647015